Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Chronic Lymphocytic Leukemia

被引：0

作者：

Tantawy, Shady I. ^{[1
]}

Timofeeva, Natalia ^{[1
]}

Fujiwara, Hitomi ^{[2
]}

Hatakeyama, Mariko ^{[2
]}

Herrera, Breana ^{[1
]}

Loza, Lizbeth ^{[1
]}

Asami, Tokiko ^{[2
]}

Ohmoto, Hiroshi ^{[2
]}

Miyamoto, Kyoko ^{[3
]}

Nishioka, Yu ^{[2
]}

Arimura, Akinori ^{[3
]}

Sawa, Masaaki ^{[2
]}

Jain, Nitin ^{[4
]}

Gandhi, Varsha ^{[1
,4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

[2] Carna Biosci Inc, Kobe, Hyogo, Japan

[3] CarnaBio USA Inc, San Francisco, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189659

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia
Schliep, S
Decker, T
Schneller, F
Wagner, H
Häcker, G
EXPERIMENTAL HEMATOLOGY, 2004, 32 (06) : 556 - 562
[32] The Gene Expression Landscape of BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia Exposed By Shallow Depth RNA Sequencing
Do, Thi Huong Lan
Lohoff, Caroline
Jung, Ferris
Benes, Vladimir
Huber, Wolfgang
Lu, Junyan
Zenz, Thorsten
BLOOD, 2023, 142
[33] Mutations detected in real world clinical sequencing during BTK inhibitor treatment in chronic lymphocytic leukemia (CLL)
Mashima, Kiyomi
Fernandes, Stacey
Shupe, Samantha
Fardoun, Rayan
Naeem, Aishath
Davids, Matthew
Brown, Jennifer
LEUKEMIA & LYMPHOMA, 2023, 64 : S20 - S22
[34] Therapy of chronic lymphocytic Leukemia Long-term Disease Control with second-Generation BTK Inhibitor
Ruedesheim, Sabine M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
[35] LOU064: A highly selective and potent covalent oral BTK inhibitor with promising pharmacodynamic effects in skin
Kaul, M.
Storim, J.
End, P.
Cabanski, M.
Jakab, A.
Schuhler, C.
Funhoff, E.
Schaefer, F.
Dimanova, E.
Kistowska, M.
Kinhikar, A.
Maiolica, A.
Sinn, A.
Fuhr, R.
Cenni, B.
ALLERGY, 2019, 74 : 332 - 332
[36] SY5609, a Potent and Selective CDK7 Inhibitor, Potentiates BTK Inhibitor Activity in Mantle Cell Lymphoma Preclinical Models
Johannessen, Liv
Henry, Susan
Sawant, Priyanka
D'Ippolito, Anthony
Ke, Nan
Lefkowitz, Ariel
Eaton, Matthew
Dworakowski, Wojciech
Rosario, Maria
Hodgson, Graeme
BLOOD, 2021, 138
[37] Preclinical activity of irreversible Menin inhibitor, BMF-219, in chronic lymphocytic leukemia.
Somanath, Priyanka
Lu, Daniel
Law, Brian
Archer, Tenley
Rughwani, Tripta
Kumar, Lekha
Kinoshita, Taisei
Balakrishnan, Mini
Butler, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[38] Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia
Walter, Harriet S.
Jayne, Sandrine
Rule, Simon A.
Cartron, Guillaume
Morschhauser, Franck
Fegan, Christopher
Yang, Yingsi
Mitra, Siddhartha
Dyer, Martin J. S.
Salles, Gilles A.
BLOOD, 2016, 128 (22)
[39] Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia
Lee-Verges, Eriong
Hanna, Bola S.
Yazdanparast, Haniyeh
Rodriguez, Vanina
Leonor Rodriguez, Marta
Giro, Ariadna
Vidal-Crespo, Anna
Rosich, Laia
Amador, Virginia
Aymerich, Marta
Villamor, Neus
Delgado, Julio
Lichter, Peter
Perez-Galan, Patricia
Lopez-Guerra, Monica
Campo, Elias
Seiffert, Martina
Colomer, Dolors
INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (11) : 2762 - 2773
[40] Preclinical characterization of HMPL-295, a potent and selective ERK 1/2 inhibitor
Hu, Jia
Ni, Jun
Lv, Yuanzhi
Li, Wenjun
Zhang, Hui
Li, Xin
Yu, Ying
Zhong, Zeyu
Wang, Jian
Sai, Yang
Qing, Weiguo
Ren, Yongxin
Shi, Michael
Su, Weiguo
CANCER RESEARCH, 2024, 84 (06)

← 1 2 3 4 5 →